title: Duration of Trastuzumab. In matters of the heart, one size may not fit all?
abstract: The PHARE trial was initially reported in 2013 and demonstrated that 6 months of Trastuzumab therapy was inferior to 12 months of therapy in terms of reducing risk of Her2+ breast cancer recurrence. Updated results of this study have been presented and demonstrate that while there is a reduction in breast cancer risk with 12 months of therapy, there is an increase in risk of cardiac events. This may have implications for patient selection, and certainly has implications for future studies. As cardiac outcomes of cancer therapies become increasingly prevalent, an integrated approach to trial design and clinical management is needed.
authors.affiliation: Medical Oncology, BC Cancer Agency, Vancouver, Canada. Electronic address: Christine.simmons@bccancer.bc.ca.
authors.forename: Christine
authors.initials: C
authors.lastname: Simmons
authors.affiliation: Medical Oncology, Ottawa Hospital Cancer Centre, Canada.
authors.forename: Susan
authors.initials: S
authors.lastname: Dent
authors.affiliation: Medical Oncology, St. Michael's Hospital, Toronto, Canada.
authors.forename: Christine
authors.initials: C
authors.lastname: Brezden-Masley
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006333:Heart Failure / Q000139:chemically induced*; D006801:Humans; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D000068878:Trastuzumab / Q000009:adverse effects*
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D000068878:Trastuzumab
keywords: Breast cancer; Cardio-toxicity; Congestive heart failure; Trastuzumab